A Phase II Study of Thalidomide in Advanced Metastatic Renal Cell Carcinoma
- 32 Downloads
Objectives: To evaluate the toxicityand activity of thalidomide in patientswith advanced metastatic renal cell cancerand to measure changes of one angiogenicfactor, vascular endothelial growth factor(VEGF)165, with therapy.
Patients and methods: 29 patients were enrolled on astudy of thalidomide using an intra-patientdose escalation schedule. Patients beganthalidomide at 400 mg/d and escalated astolerated to 1200 mg/d by day 54.Fifty-nine per cent of patients had hadprevious therapy with IL-2 and 52% wereperformance status 2 or 3. Systemic plasmaVEGF165 levels were measured by dualmonoclonal ELISA in 8 patients.
Results: 24 patients were evaluable forresponse with one partial response of 11months duration of a patient with hepaticand pulmonary metastases (4%), one minorresponse, and 2 patients stable for over 6months. Somnolence and constipation wereprominent toxicities and most patientscould not tolerate the 1200 mg/day doselevel. Systemic plasma VEGF165 levels didnot change with therapy.
Conclusion: These results are consistent with a lowlevel of activity of thalidomide in renalcell carcinoma. Administration of dosesover 800 mg/day was difficult to achieve inthis patient population, however lowerdoses were practical. The dose-responserelationship, if any, of thalidomide forrenal cell carcinoma is unclear.
Unable to display preview. Download preview PDF.
- 1.Mellin GW, Katzenstein M: The sage of thalidomide (concluded): neuropathy to embryopathy, with case reports of congenital anomalies. N Eng J Med 267:1238–1244, 1962Google Scholar
- 2.Rajkumar SV, Witzig TE: A review of angiogenesis and antiangiogenic therapy with thalidomide in multiple myeloma. Cancer Treat Rev 26(5):351–362, 2000Google Scholar
- 3.Singhal S, Mehta J, Desikan R, Ayers D, Roberson P, Eddlemon P, Munshi N, Anaissie E, Wilson C, Dhodapkar M, Zeddis J, Barlogie B: Antitumor activity of thalidomide in refractory multiple myeloma. N Eng J Med 341:1565–1571, 1999Google Scholar
- 4.Calabrese L, Fleischer AB: Thalidomide: current and potential clinical applications. Amer J Med 108(6):487–495, 2000Google Scholar
- 5.Fine HA, Figg WD, Jaeckle K, Wen PY, Kyritsis AP, Loeffler JS, Levin VA, Black PM, Kaplan R, Pluda JM, Yung WK: Phase II trial of the antiangiogenic agent thalidomide in patients with recurrent high-grade gliomas. J Clin Onc 18:708–715, 2000Google Scholar
- 6.Little RF, Wyvill KM, Pluda JM, Welles L, Marshall V, Figg WD, Newcomb FM, Tosato G, Feigel E, Steinberg SM, Whitby D, Goedert JJ, Yarchoan R: Activity of thalidomide in AIDS-related Kaposi's sarcoma. J Clin Oncol 18:2593–2602, 2000Google Scholar
- 7.Stebbins CE, Kaelin WG, Pavletich NP: Structure of the VHL-ElonginB complex: implications for VHL tumor suppressor function. Science 284:455–461, 1999Google Scholar
- 8.Blay JY, Pallardy M, Ravaud A: Serum VEGF is an independent prognostic factor in patients (pts) with metastatic renal cell carcinoma treated with IL-2 and/or IFN: analysis of the CRECY trial. Proc Amer Soc Clin Onc 18:1669, 1999Google Scholar
- 9.D'Amato RJ, Loughnan MS, Flynn E, Folkman J: Thalidomide is an inhibitor of angiogenesis. Proc Natl Acad Sci USA 91:4082–4085, 1994Google Scholar
- 10.Zeldis JB, Williams BA, Thomas SD, Elsayed ME, S.T.E.P.S.™: a comprehensive program for controlling and monitoring access to thalidomide. Clin Ther 21:319–330, 1999Google Scholar
- 11.Rodriguez CR, Fei DT, Keyt B, Baly DL: A sensitive fluorometric enzyme-linked immunosorbent assay that measures vascular endothelial growth factor165 in human plasma. J Immunological Methods 219:45–55, 1998Google Scholar
- 12.Eisen T, Boshoff C, Mak I: Continuous low dose Thalidonide: a phase II study in advanced melanoma, renal cell, ovarian and breast cancer. Brit J Cancer 82(4):812–817, 2000Google Scholar
- 13.Escudier B, Lassau N, Couanet D, Angevin E, Leborgne S, Garofano A, Mesrati F, Laplanche A: A phase II trial of Thalidomide in renal cell carcinoma. Proc Amer Soc Clin Onc 20:180a, (abstr 718), 2001Google Scholar
- 14.Li Z, Amato R, Papandreou C, Pagliaro L, Kim J, Millikan R, Loggins-Coffman J, Perez C, Logothesis C, Dalani D: Phase II Study of Thalidomide for patients with metastatic renal cell carcinoma (MRCC) progressing after interleukin-2 (IL-2)-based therapy (Rx). Proc Amer Soc Clin Onc 20:180a, (abstr 717), 2001Google Scholar
- 15.Novik Y, Dutcher JP, Larkin M, Wiernik P: Phase II study of Thalidomide(T) in advanced refractory metastatic renal cell cancer (MRCC): a single institution experience. Proc Amer Soc Clin Onc 20:265a, (abstr 1057), 2001Google Scholar
- 16.Vuky J, Berg W, Yu R, Ginsberg M, Mazumdar M, Bacik J, Motzer R: Phase II trial of Thalidomide in patients with metastatic renal cell carcinoma. Proc Amer Soc Clin Onc 20:265a, (abstr 1056), 2001Google Scholar
- 17.Stebbing J, Benson C, Eisen T, Pyle L, Smalley K, Bridle H, Mak I, Sapunar F, Ahern R, Gore ME: The treatment of advanced renal cell cancer with high-dose oral thalidomide. Br J Cancer 85:953–958, 2001Google Scholar
- 18.Zangari M, Anissie E, Barlogie B, Badros A, Desikan R, Gopal AV, Morris C, Toor A, Siegel E, Fink L, Tricot G: Increased risk of deep-vein thrombosis in patients with multiple myeloma receiving thalidomide and chemotherapy. Blood 98:1614–1615, 2001Google Scholar
- 19.Escudier B, Lassau N, Leborgne S, Angevin E, Laplanche A: Thalidomide and venous thrombosis. Ann Int Med 136:711–712, 2002Google Scholar